Table 1.
Clinicopathological and Molecular Correlations of the CAF Score in DDTC Patients from the GSE76039 Cohort
| Variables | N | Wu CAF Score | p value | Nurmik CAF Score | p value | Calon CAF Score | p value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Low-Risk | High-Risk | Low-Risk | High-Risk | Low-Risk | High-Risk | |||||
| Age (years) Mean±SD |
37 | 64.16±15.39 | 66.94±12.04 | 0.545 | 65.42±14.71 | 65.61±13.06 | 0.967 | 64.00±14.94 | 67.11±12.58 | 0.499 |
| Gender | 1.000 | 0.242 | 1.000 | |||||||
| Male | 3 | 2 (66.7%) | 1 (33.3%) | 1 (33.3%) | 2 (66.7%) | 2 (66.7%) | 1 (33.3%) | |||
| Female | 12 | 7 (58.3%) | 5 (41.7%) | 9 (75.0%) | 3 (25.0%) | 8 (66.7%) | 4 (33.3%) | |||
| Histology | 0.009 | 0.049 | 0.009 | |||||||
| PDTC | 19 | 14 (73.7%) | 5 (26.3%) | 13 (68.4%) | 6 (31.6%) | 14 (73.7%) | 5 (26.3%) | |||
| ATC | 18 | 5 (27.8%) | 13 (72.2%) | 6 (33.3%) | 12 (66.7%) | 5 (27.8%) | 13 (72.2%) | |||
| T Stage | 0.192 | 1.000 | 1.000 | |||||||
| T1-T2 | 2 | 2 (100.0%) | 0 (0.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | |||
| T3-T4 | 27 | 11 (40.7%) | 16 (59.3%) | 13 (48.1%) | 14 (51.9%) | 11 (40.7%) | 16 (59.3%) | |||
| LNM | 0.007 | 0.046 | 0.007 | |||||||
| N0 | 10 | 8 (80.0%) | 2 (20.0%) | 8 (80.0%) | 2 (20.0%) | 8 (80.0%) | 2 (20.0%) | |||
| N1 | 17 | 4 (23.5%) | 13 (76.5%) | 6 (35.3%) | 11 (64.7%) | 4 (23.5%) | 13 (76.5%) | |||
| Distant metastasis | 0.660 | 1.000 | 0.640 | |||||||
| M0 | 6 | 4 (66.7%) | 2 (33.3%) | 4 (66.7%) | 2 (33.3%) | 4 (66.7%) | 2 (33.3%) | |||
| M1 | 17 | 9 (52.9%) | 8 (47.1%) | 10 (58.8%) | 7 (41.2%) | 8 (47.1%) | 9 (52.9%) | |||
| Mutation count | 35 | 6.59±4.82 | 9.11±8.96 | 0.311 | 9.71±8.94 | 6.17±4.89 | 0.152 | 8.00±8.23 | 7.78±6.46 | 0.930 |
| BRAF V600E | 0.091 | <0.001 | 0.002 | |||||||
| Mutation | 13 | 4 (30.8%) | 9 (69.2%) | 1 (7.7%) | 12 (92.3%) | 2 (6.7%) | 11 (84.6%) | |||
| Wild-type | 24 | 15 (62.5%) | 9 (37.5%) | 18 (75.0%) | 6 (25.0%) | 17 (70.8%) | 7 (29.2%) | |||
| RAS | 0.295 | 0.013 | 0.295 | |||||||
| Mutation | 12 | 8 (66.7%) | 4 (33.3%) | 10 (83.3%) | 2 (16.7%) | 8 (66.7%) | 4 (33.3%) | |||
| Wild-type | 25 | 11 (44.0%) | 14 (56.0%) | 9 (36.0%) | 16 (64.0%) | 11 (44.0%) | 14 (56.0%) | |||
| EIF1AX | 1.000 | 0.046 | 0.340 | |||||||
| Mutation | 5 | 3 (60.0%) | 2 (40.0%) | 5 (100.0%) | 0 (0.0%) | 4 (80.0%) | 1 (20.0%) | |||
| Wild-type | 32 | 16 (50.0%) | 16 (50.0%) | 14 (43.8%) | 18 (56.3%) | 15 (46.9%) | 17 (53.1%) | |||
| TERT promoter | 0.515 | 0.049 | 0.049 | |||||||
| Mutation | 20 | 9 (45.0%) | 11 (55.0%) | 7 (35.0%) | 13 (65.0%) | 7 (35.0%) | 13 (65.0%) | |||
| Wild-type | 17 | 10 (58.8%) | 7 (41.2%) | 12 (70.6%) | 5 (29.4%) | 12 (70.6%) | 5 (29.4%) | |||
| TP53 | 0.049 | 0.515 | 0.049 | |||||||
| Mutation | 16 | 5 (31.3%) | 11 (68.8%) | 7 (43.8%) | 9 (56.3%) | 5 (31.3%) | 11 (68.8%) | |||
| Wild-type | 21 | 14 (66.7%) | 7 (33.3%) | 12 (57.1%) | 9 (42.9%) | 14 (66.7%) | 7 (33.3%) | |||
| PI3KCA/AKT/mTOR | 0.062 | 0.269 | 0.062 | |||||||
| Mutation | 9 | 2 (22.2%) | 7 (77.8%) | 3 (33.3%) | 6 (66.7%) | 2 (22.2%) | 7 (77.8%) | |||
| Wild-type | 28 | 17 (60.7%) | 11 (39.3%) | 16 (57.1%) | 12 (42.9%) | 17 (60.7%) | 11 (39.3%) | |||
Note: Italic and bold type indicates statistical significance.
Abbreviations: CAF, cancer-associated fibroblast; SD, standard deviation; NA, not available; PDTC, poorly differentiated thyroid cancer; ATC, anaplastic thyroid cancer; LNM, lymph node metastasis.